RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Swedish Orphan Biovitrum AB (publ) Revenue 2024

Swedish Orphan Biovitrum AB (publ) Revenue

24.85 B SEK

Swedish Orphan Biovitrum AB (publ) Dividend yield

Ticker

SOBI.ST

ISIN

SE0000872095

WKN

A0LA5K

In 2024, Swedish Orphan Biovitrum AB (publ)'s sales reached 24.85 B SEK, a 12.3% difference from the 22.12 B SEK sales recorded in the previous year.

The Swedish Orphan Biovitrum AB (publ) Revenue history

YEARREVENUE (undefined SEK)GROSS MARGIN (%)
2029e36.7746,70
2028e35.1448,86
2027e33.2651,62
2026e31.2254,99
2025e28.0361,25
2024e24.8569,11
202322.1277,62
202218.7976,51
202115.5377,56
202015.2678,87
201914.2576,59
20189.1473,57
20176.5171,52
20165.270,14
20153.2362,17
20142.6159,37
20132.1858,99
20121.9254,10
20111.9151,00
20101.9164,04
20091.371,03
20081.1476,79
20071.2672,25
20061.275,54
20050.9471,10
20040.6561,52

Swedish Orphan Biovitrum AB (publ) Aktienanalyse

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (Sobi) is a Swedish biotechnology company specializing in rare diseases. It was founded in 1986 as Swedish Orphan International and renamed Swedish Orphan Biovitrum AB (Sobi) in 2007. Sobi is headquartered in Stockholm and is listed on NASDAQ OMX Stockholm. Its business model focuses on developing and marketing therapies for rare diseases with limited treatment options. Sobi operates in Europe, the Middle East, North Africa, and North America, collaborating closely with patient organizations and medical professionals to raise awareness of rare diseases and provide patients with access to important therapies. The company is divided into three business areas: Hemophilia, Inflammatory Diseases, and Genetic Diseases. Sobi offers medications for bleeding disorders, inflammatory diseases, and lysosomal storage diseases, among others. Some of its key products include Elocta and Alprolix for Hemophilia A and B, Kineret for autoinflammatory diseases, Synagis for respiratory syncytial virus (RSV) infections in children, Vimizim for mucopolysaccharidosis type IVA, and Orfadin for hereditary tyrosinemia type 1. In conclusion, Sobi is a leading biotechnology company dedicated to developing and marketing therapies for rare diseases, with a wide range of products in its portfolio. It collaborates with patient organizations and strives to improve the quality of life for patients with rare diseases. Swedish Orphan Biovitrum AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Swedish Orphan Biovitrum AB (publ)'s Sales Figures

The sales figures of Swedish Orphan Biovitrum AB (publ) originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Swedish Orphan Biovitrum AB (publ)’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Swedish Orphan Biovitrum AB (publ)'s sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Swedish Orphan Biovitrum AB (publ)’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Swedish Orphan Biovitrum AB (publ) Stock

How much revenue did Swedish Orphan Biovitrum AB (publ) generate this year?

Swedish Orphan Biovitrum AB (publ) has achieved a revenue of 24.85 B SEK this year.

How much was the turnover of the company Swedish Orphan Biovitrum AB (publ) compared to the previous year?

The revenue of Swedish Orphan Biovitrum AB (publ) has increased by 12.3% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Swedish Orphan Biovitrum AB (publ)?

The revenue of Swedish Orphan Biovitrum AB (publ) is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Swedish Orphan Biovitrum AB (publ) measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Swedish Orphan Biovitrum AB (publ) so important for investors?

The revenue of Swedish Orphan Biovitrum AB (publ) is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Swedish Orphan Biovitrum AB (publ) pay?

Over the past 12 months, Swedish Orphan Biovitrum AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Swedish Orphan Biovitrum AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Swedish Orphan Biovitrum AB (publ)?

The current dividend yield of Swedish Orphan Biovitrum AB (publ) is .

When does Swedish Orphan Biovitrum AB (publ) pay dividends?

Swedish Orphan Biovitrum AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Swedish Orphan Biovitrum AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Swedish Orphan Biovitrum AB (publ) located?

Swedish Orphan Biovitrum AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Swedish Orphan Biovitrum AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Swedish Orphan Biovitrum AB (publ) from 5/28/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Swedish Orphan Biovitrum AB (publ) pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Swedish Orphan Biovitrum AB (publ) in the year 2023?

In the year 2023, Swedish Orphan Biovitrum AB (publ) distributed 0 SEK as dividends.

In which currency does Swedish Orphan Biovitrum AB (publ) pay out the dividend?

The dividends of Swedish Orphan Biovitrum AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Swedish Orphan Biovitrum AB (publ)

Our stock analysis for Swedish Orphan Biovitrum AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Swedish Orphan Biovitrum AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.